SPOTLIGHT -
Vice President, Medical Affairs – Migraine, Impel Neuropharma
Clinical Takeaways From INP104 Data in Migraine: Sheena K. Aurora, MD
The vice president of Medical Affairs in Migraine at Impel discussed the clinical takeaways from the STOP 301 trial of intranasal DHE and the advantages that the novel formulation might offer patients with migraine.
Advantages and Safety Profile of INP104: Sheena K. Aurora, MD
The vice president of Medical Affairs in Migraine at Impel discussed the STOP 301 trial of intranasal DHE and how the safety profile offers a positive for patients who would use the agent on-demand.
The Broad Receptor Profile of DHE: Sheena K. Aurora, MD
The vice president of Medical Affairs in Migraine at Impel discussed the gaps in care that novel dihydroergotamine formulations, such as INP104, might be able to fill for patients with migraine.
